6.
Yang A, Wistuba-Hamprecht K, Greten T, Ruf B
. Innate-like T cells in liver disease. Trends Immunol. 2024; 45(7):535-548.
DOI: 10.1016/j.it.2024.05.008.
View
7.
Harly C, Guillaume Y, Nedellec S, Peigne C, Monkkonen H, Monkkonen J
. Key implication of CD277/butyrophilin-3 (BTN3A) in cellular stress sensing by a major human γδ T-cell subset. Blood. 2012; 120(11):2269-79.
PMC: 3679641.
DOI: 10.1182/blood-2012-05-430470.
View
8.
Herold N, Schollhorn A, Feile A, Gaissler A, Mohrholz A, Pawelec G
. Integrin activation enables rapid detection of functional Vδ1 and Vδ2 γδ T cells. Eur J Immunol. 2022; 52(5):730-736.
DOI: 10.1002/eji.202149682.
View
9.
Bennouna J, Bompas E, Neidhardt E, Rolland F, Philip I, Galea C
. Phase-I study of Innacell gammadelta, an autologous cell-therapy product highly enriched in gamma9delta2 T lymphocytes, in combination with IL-2, in patients with metastatic renal cell carcinoma. Cancer Immunol Immunother. 2008; 57(11):1599-609.
PMC: 11030608.
DOI: 10.1007/s00262-008-0491-8.
View
10.
Hedemann N, Rogmans C, Sebens S, Wesch D, Reichert M, Schmidt-Arras D
. ADAM17 inhibition enhances platinum efficiency in ovarian cancer. Oncotarget. 2018; 9(22):16043-16058.
PMC: 5882316.
DOI: 10.18632/oncotarget.24682.
View
11.
Saura-Esteller J, de Jong M, King L, Ensing E, Winograd B, de Gruijl T
. Gamma Delta T-Cell Based Cancer Immunotherapy: Past-Present-Future. Front Immunol. 2022; 13:915837.
PMC: 9245381.
DOI: 10.3389/fimmu.2022.915837.
View
12.
de Weerdt I, Lameris R, Scheffer G, Vree J, de Boer R, Stam A
. A Bispecific Antibody Antagonizes Prosurvival CD40 Signaling and Promotes Vγ9Vδ2 T cell-Mediated Antitumor Responses in Human B-cell Malignancies. Cancer Immunol Res. 2020; 9(1):50-61.
DOI: 10.1158/2326-6066.CIR-20-0138.
View
13.
Wesch D, Kabelitz D, Oberg H
. Tumor resistance mechanisms and their consequences on γδ T cell activation. Immunol Rev. 2020; 298(1):84-98.
DOI: 10.1111/imr.12925.
View
14.
Deaglio S, Dwyer K, Gao W, Friedman D, Usheva A, Erat A
. Adenosine generation catalyzed by CD39 and CD73 expressed on regulatory T cells mediates immune suppression. J Exp Med. 2007; 204(6):1257-65.
PMC: 2118603.
DOI: 10.1084/jem.20062512.
View
15.
Mensurado S, Condeco C, Sanchez-Martinez D, Shirley S, Coelho R, Tirado N
. CD155/PVR determines acute myeloid leukemia targeting by Delta One T cells. Blood. 2024; 143(15):1488-1495.
PMC: 11033583.
DOI: 10.1182/blood.2023022992.
View
16.
Xu Y, Xiang Z, Alnaggar M, Kouakanou L, Li J, He J
. Allogeneic Vγ9Vδ2 T-cell immunotherapy exhibits promising clinical safety and prolongs the survival of patients with late-stage lung or liver cancer. Cell Mol Immunol. 2020; 18(2):427-439.
PMC: 8027668.
DOI: 10.1038/s41423-020-0515-7.
View
17.
Oberg H, Kellner C, Gonnermann D, Sebens S, Bauerschlag D, Gramatzki M
. Tribody [(HER2)xCD16] Is More Effective Than Trastuzumab in Enhancing γδ T Cell and Natural Killer Cell Cytotoxicity Against HER2-Expressing Cancer Cells. Front Immunol. 2018; 9:814.
PMC: 5916959.
DOI: 10.3389/fimmu.2018.00814.
View
18.
Gober H, Kistowska M, Angman L, Jeno P, Mori L, De Libero G
. Human T cell receptor gammadelta cells recognize endogenous mevalonate metabolites in tumor cells. J Exp Med. 2003; 197(2):163-8.
PMC: 2193814.
DOI: 10.1084/jem.20021500.
View
19.
Herold N, Bruhns M, Babaei S, Spreuer J, Castagna A, Yurttas C
. High-dimensional in situ proteomics imaging to assess γδ T cells in spatial biology. J Leukoc Biol. 2024; 115(4):750-759.
DOI: 10.1093/jleuko/qiad167.
View
20.
Peipp M, Wesch D, Oberg H, Lutz S, Muskulus A, van de Winkel J
. CD20-Specific Immunoligands Engaging NKG2D Enhance γδ T Cell-Mediated Lysis of Lymphoma Cells. Scand J Immunol. 2017; 86(4):196-206.
DOI: 10.1111/sji.12581.
View